Erlmeier Franziska, Weichert Wilko, Autenrieth Michael, Wiedemann Max, Schrader Andres Jan, Hartmann Arndt, Ivanyi Philipp, Steffens Sandra
Institute of Pathology, Technical University Munich (TUM), Trogerstraße 18, 81675, Munich, Germany.
Member of the German Renal Cell Tumor Consortium, Jena, Germany.
Med Oncol. 2017 May;34(5):71. doi: 10.1007/s12032-017-0926-1. Epub 2017 Mar 28.
In the context of cancer immunotherapy, PD-1 as well as PD-L1 has been widely studied in renal cell carcinoma (RCC). PD-1 and PD-L1 play a significant role as prognostic markers in clear cell renal cell carcinoma. In contrast, little is known about PD-L2 expression patterns in RCC, especially in rarer subtypes. The aim of this study was to evaluate the prevalence, distribution and prognostic impact of PD-L2 expression in chromophobe (ch)RCC. Eighty-one patients who underwent renal surgery due to chRCC were retrospectively evaluated. Tumor specimens were analyzed for PD-L2 expression by immunohistochemistry. Expression data were associated with clinicopathological parameters and overall survival (OS). Twenty-three (28.4%) patients showed a PD-L2 > median (PD-L2 high) staining intensity. No significant association between clinicopathological parameters and PD-L2 expression was identified. A significant difference between 5- and 10-year OS in dependence of PD-L2 expression was found (PD-L2 low 96.4 and 87.7% vs. PD-L2 high 87.1 and 56%; log rank, p = 0.029). However, in multivariate analysis PD-L2 expression failed to be proofed as an independent prognostic factor. In conclusion, to our knowledge this is the first study evaluating the prognostic impact of PD-L2 in a considerably large cohort of chRCC. Our results showed a significant diminished OS in dependence of PD-L2 expression. This implicates that PD-L2 might play a role as prognostic marker in chRCC demanding further evaluation.
在癌症免疫治疗的背景下，程序性死亡受体1（PD-1）以及程序性死亡受体配体1（PD-L1）已在肾细胞癌（RCC）中得到广泛研究。PD-1和PD-L1在透明细胞肾细胞癌中作为预后标志物发挥着重要作用。相比之下，人们对RCC中PD-L2的表达模式了解甚少，尤其是在罕见亚型中。本研究的目的是评估PD-L2在嫌色性（ch）RCC中的表达情况、分布及预后影响。对81例因chRCC接受肾脏手术的患者进行了回顾性评估。通过免疫组织化学分析肿瘤标本中PD-L2的表达。将表达数据与临床病理参数及总生存期（OS）相关联。23例（28.4%）患者的PD-L2染色强度>中位数（PD-L2高）。未发现临床病理参数与PD-L2表达之间存在显著关联。发现根据PD-L2表达，5年和10年总生存期存在显著差异（PD-L2低为96.4%和87.7%，而PD-L2高为87.1%和56%；对数秩检验，p = 0.029）。然而，在多变量分析中，PD-L2表达未能被证明是一个独立的预后因素。总之，据我们所知，这是第一项评估PD-L2在相当大的chRCC队列中的预后影响的研究。我们的结果显示，根据PD-L2表达，总生存期显著缩短。这意味着PD-L2可能在chRCC中作为预后标志物发挥作用，需要进一步评估。
